“NordicCan A/S Develops Innovative Cannabinoid Lozenges”
NordicCan A/S has filed a patent application for a cannabinoid lozenge formulation, which may offer enhanced bioavailability and targeted delivery of cannabinoids. The claimed invention involves a specific combination of excipients and APIs to create a lozenge that can be easily administered orally. This novel formulation could potentially address issues with traditional cannabis products.
Clinical Perspective & Therapeutic Significance
Novel cannabinoid delivery systems offer potential advantages in bioavailability and standardized dosing.
Intellectual Property & Market Landscape
This patent application reflects ongoing intellectual property investment by NordicCan A/S.
“”This novel lozenge formulation has the potential to improve cannabinoid bioavailability and targeted delivery, which could lead to enhanced therapeutic efficacy in various conditions.””
